2020 ASH Annual Meeting & Exposition
ASH 2020: Ruxolitinib for Steroid-Refractory/Steroid-Dependent Chronic Graft-vs-Host Disease
Ruxolitinib was superior to best available therapy in achieving efficacy as determined by overall response and duration of response, with acceptable safety in adolescents and adults with steroid-depen...
Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes
Ann-Kathrin Eisfeld, MD, of The Ohio State University Comprehensive Cancer Center, discusses SEER data showing that patients with acute myeloid leukemia who are Black and younger than age 60 may have ...
ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies
The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophyla...
ASH 2020: Does Race Contribute to Poor Outcomes in Younger Black Patients Diagnosed With AML?
It has been well documented that, collectively, Black individuals have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also hav...
ASH 2020: Study Examines Impact of Neighborhood Socioeconomic Status on Outcomes in Minority Patients With AML
Studies show that non-Hispanic Black and Hispanic patients with acute myeloid leukemia (AML) have higher mortality rates than non-Hispanic White patients diagnosed with the disease, despite lower rate...
